MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness products, comprising medicines, vitamins, medical devices, and test kits; and offers consumer goods, such as home and personal care products, including toiletries, baby care products, soaps and detergents, and sanitizers. The company also provides wholesale cash and carry; diagnostic, pathological, and laboratory testing services, as well as engages in the contract manufacturing of private label pharmaceuticals. It operates stores in Telangana, Andhra Pradesh, Karnataka, Tamil Nadu, West Bengal, Maharashtra, Orissa, Madhya Pradesh, Chhattisgarh, Kerala, and Puducherry, as well as online platform. The company was incorporated in 2006 and is based in Hyderabad, India.
Revenue projections:
Revenue projections for MEDPLUS Investors are expected to be cautious with MEDPLUS, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.
Financial Ratios:
currentRatio
0.000000
forwardPE
38.595173
debtToEquity
64.360000
earningsGrowth
1.942000
revenueGrowth
0.036000
grossMargins
0.253480
operatingMargins
0.042210
trailingEps
14.820000
forwardEps
15.120000
MedPlus Health Services Limited's forward EPS is greater than its trailing EPS, indicating that the company is expected to deliver higher profitability this year. This suggests that MedPlus Health Services Limited is projected to improve its earnings, reflecting positive growth compared to last year's financial performance.
Price projections:
Price projections for MEDPLUS MedPlus Health Services Limited's price projections have been revised upward over time, suggesting that analysts are becoming more confident in the company's future. This trend points to increased optimism about MedPlus Health Services Limited's ability to grow.
Recommendation changes over time:
Recommendations trend for MEDPLUS
Analysts have maintained a buy bias for MEDPLUS, which could prompt investors to consider the stock as a viable investment. With this positive outlook, MEDPLUS is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
The article discusses the implications of the Eurozone CPI at 2.1% regarding...
By clicking "Accept", you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our tailored marketing efforts.